Apolipoprotein B (Apo-B) Test
The Apo-B test measures serum apolipoprotein B, the structural protein present as a single copy on each atherogenic lipoprotein particle (VLDL, IDL, LDL, Lp(a)). It directly enumerates particle number, correlating more strongly with cardiovascular risk than LDL-cholesterol, and is especially informative in metabolic syndrome, diabetes, and hypertriglyceridaemia where small dense LDL predominates.
1
Biomarkers
Blood (serum)
Sample
3–5 business days
Turnaround
Preferred but not mandatory
Fasting
What is the Apo-B test?
The Apolipoprotein B (Apo-B) Test quantifies the serum concentration of apolipoprotein B, the principal protein component of atherogenic lipoproteins. Each VLDL, IDL, LDL, and Lp(a) particle carries exactly one Apo-B molecule, so the Apo-B level directly counts the number of potentially atherogenic particles in circulation — a measure that correlates more strongly with atherosclerotic cardiovascular disease than traditional cholesterol metrics. Practitioners order Apo-B when LDL-cholesterol and triglyceride results do not fully capture risk — especially in patients with metabolic syndrome, diabetes, or familial combined hyperlipidaemia, where small dense LDL particles predominate and cholesterol concentration underestimates true particle burden. Apo-B also refines residual-risk assessment in patients already on lipid-lowering therapy, guides intensification decisions when standard targets are met but risk remains, and resolves discordance between calculated LDL-cholesterol and non-HDL-cholesterol in hypertriglyceridaemic states.
What does the Apo-B test measure?
Apolipoprotein B is a large structural apolipoprotein, present as a single copy on each atherogenic lipoprotein particle — very-low-density lipoprotein, intermediate-density lipoprotein, low-density lipoprotein, and lipoprotein(a). Unlike cholesterol concentration, which reflects the total cholesterol cargo carried by these particles, Apo-B provides a direct count of circulating atherogenic particles. It remains bound throughout the lifespan of each particle, mediating receptor binding and clearance via the hepatic LDL receptor and serving as the essential structural scaffold for triglyceride and cholesterol transport from the liver and intestine.
Apo-B is increasingly recognised as a more accurate marker of cardiovascular risk than LDL-cholesterol or non-HDL-cholesterol, because it enumerates the number of atherogenic particles rather than their cholesterol content. Patients with discordance — high particle number despite moderate LDL-cholesterol — carry greater risk, a pattern common in metabolic syndrome, insulin resistance, and hypertriglyceridaemia. International lipid guidelines now position Apo-B as a preferred target for risk assessment and treatment decisions, particularly when LDL-cholesterol and triglycerides do not align or when residual risk persists despite statin therapy.
Why is the Apo-B test ordered?
- Assessment of cardiovascular risk in patients with metabolic syndrome, type 2 diabetes, or insulin resistance, where small dense LDL particles may be underestimated by LDL-cholesterol
- Evaluation of residual cardiovascular risk in statin-treated patients who have reached LDL-cholesterol targets but remain at elevated clinical risk
- Investigation of suspected familial combined hyperlipidaemia or familial dysbetalipoproteinaemia, where particle number and cholesterol content diverge
- Clarification of cardiovascular risk when LDL-cholesterol and non-HDL-cholesterol are discordant, particularly in the setting of hypertriglyceridaemia
- Monitoring response to lipid-lowering therapy in patients where particle reduction is the therapeutic goal, including those on PCSK9 inhibitors or ezetimibe
- Screening for atherogenic dyslipidaemia in patients with chronic kidney disease, where standard lipid panels may underestimate particle burden
- Risk stratification in patients with borderline or intermediate 10-year cardiovascular risk scores, to refine primary prevention treatment decisions
- Assessment of patients with elevated lipoprotein(a), since Lp(a) particles contain Apo-B and contribute to the total atherogenic particle count
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
Preferred but not mandatory
Collection method
Venipuncture at patient service centre
Turnaround
3–5 business days
Collection notes
Phlebotomy required. Apo-B itself is minimally affected by fasting status, but concomitant lipid panel analytes (triglycerides, calculated LDL-cholesterol) require fasting, so an 8–12 hour fast is preferred. Avoid acute illness; defer testing until at least four to six weeks after infection, surgery, or myocardial infarction.
Specimen requirements
Minimum 0.5 mL serum in a serum separator tube. Separate from cells within two hours of collection; Apo-B is stable refrigerated for up to one week or frozen for longer storage. Note the performing laboratory and assay method for serial comparability.
What can affect Apo-B results?
Apo-B is minimally affected by recent food intake compared with triglycerides, and can be measured non-fasting; however, most lipid panels are drawn fasting for consistency with LDL-cholesterol and triglycerides.
The acute-phase response transiently lowers circulating lipoproteins including Apo-B; defer testing until at least four to six weeks after resolution of acute illness or major surgery.
Physiological hyperlipidaemia of pregnancy raises Apo-B in the second and third trimesters; lipid assessment for cardiovascular risk is typically deferred until several months postpartum.
Thyroid hormone deficiency impairs LDL-receptor-mediated clearance, raising LDL and Apo-B; screen and treat thyroid dysfunction before attributing dyslipidaemia to primary causes.
Ciclosporin, tacrolimus, and some antiretroviral agents can raise Apo-B through hepatic and lipoprotein metabolic effects; drug history is essential to interpretation.
Apo-B assays differ by platform and calibrator; serial monitoring should use the same laboratory and method for comparability.
What do Apo-B results mean?
Elevated
High Apo-B (>100–120 mg/dL in moderate-risk, >80 mg/dL in high-risk populations) indicates an increased number of atherogenic particles and confers elevated cardiovascular risk independent of LDL-cholesterol. Common causes include familial combined hyperlipidaemia, metabolic syndrome, insulin resistance, nephrotic syndrome, and hypothyroidism. Elevated Apo-B with only modestly raised LDL-cholesterol signals a predominance of small dense LDL particles and justifies more intensive lipid-lowering therapy. Levels persistently above guideline targets despite statin therapy define residual risk and may prompt addition of ezetimibe, PCSK9 inhibitors, or other agents.
Normal
Apo-B within the reference range (approximately 40–100 mg/dL, depending on age and sex) generally correlates with lower cardiovascular risk, though guideline-based optimal targets (<80–100 mg/dL) are stricter than laboratory reference intervals. A normal Apo-B reassures when LDL-cholesterol is borderline, but clinical context — family history, comorbidities, imaging — remains essential to overall risk stratification.
Reduced
Low Apo-B (<40–50 mg/dL) is typically seen in malabsorption syndromes, severe malnutrition, hyperthyroidism, or genetic abetalipoproteinaemia and hypobetalipoproteinaemia. It is not a cardiovascular risk factor; rather, very low values may signal an underlying metabolic or genetic disorder requiring further investigation.
Note: Apo-B must be interpreted alongside the lipid panel (LDL-cholesterol, non-HDL-cholesterol, triglycerides, HDL-cholesterol) and clinical risk score; it is most informative when discordant with LDL-cholesterol. Reference limits and optimal targets differ — guidelines favour lower therapeutic thresholds than traditional laboratory ranges. Assay standardisation is ongoing; serial results should use the same laboratory for trend analysis.
Frequently asked questions
Apo-B counts the number of atherogenic particles directly, while LDL-cholesterol measures only the cholesterol cargo they carry. When small dense LDL particles predominate — common in metabolic syndrome and diabetes — LDL-cholesterol underestimates true particle burden and cardiovascular risk, whereas Apo-B captures the full atherogenic load.
How to access the Apo-B test
The Apo-B reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Mach F, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. (2020)
- Sniderman AD, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. (2019)
- Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. (2019)
- Wilkins JT, et al. Discordance between apolipoprotein B and LDL-cholesterol in young adults predicts coronary artery calcification: the CARDIA study. J Am Coll Cardiol. (2016)
- Pearson GJ, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. (2021)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.